For Formulation teams developing high-concentration biologic formulations
Aggregation propensity, viscosity proxies, and formulation ranking at concentrations where DLS saturates and B22 measurement is too slow to scale.
Both channels operate at high concentration — no dilution, no DLS saturation, no slow B22 setup.
The ORYL F1, using Ultrafast Light Scattering. Its Second Harmonic Scattering readout stays linear past 50 mg/mL — validated to hundreds of mg/mL on proteins and oligonucleotides, and linear to over 50 mg/mL on BSA at R-squared 0.99 — where DLS, SLS and nephelometry saturate. It measures the undiluted formulation in a 384-well plate in about 15 minutes.
At high concentration, DLS saturates above about 10 mg/mL and suffers from multiple scattering that distorts the autocorrelation function and makes size readouts unreliable; SEC requires dilution that disrupts the aggregation equilibrium, and viscometry is material-hungry and only gives a late-stage signal. The ORYL F1 is a high-throughput alternative that reads the native, undiluted state directly via SHS and LLS.
The ORYL F1 quantifies the operational onset of aggregation directly in aqueous oligonucleotide solutions at formulation-relevant concentrations, using only 50 to 100 microlitres per condition, without dilution or labelling.
Yes — a distinction turbidity and DLS generally cannot make. Because SHS reads the native state, dilution experiments show whether an aggregated formulation recovers its monomeric baseline (reversible) or not (irreversible).
50 to 100 microlitres per well in a standard 384-well plate, measured non-destructively in about 15 minutes, so the same wells can be re-measured over time for stability tracking.
Monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), peptides, oligonucleotides and conjugates — the dual-readout method is modality-agnostic and validated across proteins and oligonucleotides.
De-risk solubility and aggregation in your pipeline — early, with low-compound, plate-based measurement.